Ekterly
Ekterly ingredients
| Active ingredient | Strength |
|---|---|
| Sebetralstat | 300 mg/1 |
What Ekterly is used for
The FDA lists the approved uses on the official label (below). In the EU, sebetralstat is approved as Ekterly for:
Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Ekterly
- Generic name
- Sebetralstat
- Made by
- KalVista Pharmaceuticals Ltd
- Forms
- Tablet
- Given
- Oral
- Drug class
- Plasma Kallikrein Inhibitor
- FDA approval
- New drug application (NDA) NDA219301
- On the US market since
- 2025
Official information
- Ekterly prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Sebetralstat)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Ekterly?
Ekterly (Sebetralstat) is a specialist medicine made by KalVista Pharmaceuticals Ltd, approved by the US FDA.
What are the ingredients of Ekterly?
Ekterly contains Sebetralstat (300 mg/1).
Is Ekterly approved in Europe?
The same active substance is approved in the EU as Ekterly.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA